Drug Discovery & Development
CRISPR phage offers precision medicine tool to fight bacterial infections
In an attempt to combat bacterial infections, Locus Biosciences is developing bacteriophage therapies that deliver CRISPR-Cas3 machinery directly to specific, targeted pathogens to obliterate them. Locus CEO Paul Garofolo discusses the company's technology and recent updates with The ScienceBoard.net.  Discuss
Pfizer, BioNTech just days away from applying for EUA for COVID-19 vaccine
Pfizer and BioNTech have passed another milestone in their effort to deliver a vaccine for the SARS-CoV-2 virus. The companies on November 18 reported that their BNT162b2 vaccine candidate has met safety milestones and that they plan to apply for an emergency use authorization (EUA) from the U.S. Food and Drug Administration for the product in the coming days.  Discuss
If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors, according to a new report from Kalorama Information, which estimates the market for COVID-19 vaccines could be as high as $27 billion.  Discuss
Canadian experts discuss somatic gene therapy approval and use
Gene therapies offer great benefits to patients but could strain healthcare budgets and exacerbate existing treatment inequities in Canada, according to an expert panel that was commissioned to write a report by the Council of Canadian Academies.  Discuss
FDA issues guidance on submitting EUA requests for COVID-19 vaccines
The U.S. Food and Drug Administration (FDA) on October 6 issued a new guidance with recommendations for developers of COVID-19 vaccines regarding the scientific data and information that would be required to support emergency use authorization (EUA) for the products.  Discuss
Is 'bespoke' therapy the future of genomic medicine?
Gene therapies hold extremely exciting promise for meeting the unmet needs of many individuals with genetic diseases, as discussed in a session of the second annual American Society of Gene & Cell Therapy Policy Summit on September 24.  Discuss
Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of customization, manufacturing expertise, and years' worth of knowledge.  Discuss
Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming months. Such collaboration could change the way that innovation and competition are viewed in the biopharmaceutical industry, according to a policy forum published in Science on August 13.  Discuss
Biosimulation can mitigate risk of COVID-19 drug development
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation -- using computers to simulate drug response in humans -- can help accelerate the process, which Certara hopes to achieve with a newly launched platform targeted at COVID-19 vaccine development.  Discuss
Transparency helps maintain scientific integrity of clinical trials
A new study offers reassuring evidence about the integrity of registered clinical trials, with researchers finding no signs of widespread manipulation of results regarding statistical significance thresholds. The study results were published in the Proceedings of the National Academy of Sciences on June 2.  Discuss
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter